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SUMMARY
Colorectal cancer (CRC) is a leading cause of cancer incidence and
mortality. It is well known that an important fraction of CRC risk is
accounted by genetic factors. Identifying and characterising such
factors may aid in identifying high-risk individuals who will benefit
from effective preventive interventions.
PREVENTATIVE MEASURES
Colorectal cancer (CRC) is a leading global cause of cancer
incidence and mortality. After lung and breast cancer, it is the
third most commonly diagnosed malignancy, with 1.36 million
new patients diagnosed annually.1 Despite this large public health
burden, most CRCs could be prevented through screening for pre-
malignant lesions (polyps).2 Several CRC prevention programmes
are already in place in countries with socialised medical systems,
and these have resulted in a shift towards higher incidence of
early-stage CRCs and a concomitant improvement in survival
outcomes.3–5 Preventive interventions could benefit further from
tools to identify high-risk groups. About a third of the CRC risk
variance is attributable to inherited factors,6 and hence, genetic-
based strategies offer great opportunities to identify high-risk
individuals who could benefit from prevention and early
detection.
The past decade has seen several advances in our under-
standing of the genetic aetiology of CRC. Through approaches
that include linkage analysis, which involves genetic studies of
disease co-segregation among affected relatives, and genome-
wide association studies (GWAS), which involve comparing gene
frequency data between CRC patients and healthy controls, 14
highly penetrant genes and >40 low-penetrance variants have so
far been identified for CRC.7,8 These genes and variants only
explain around 14% of the inherited risk of CRC9 and with most of
these remaining relatively poorly understood. There is thus a clear
need for additional discovery and functional studies to allow
translation of these genetic findings into improved prevention
strategies. In this issue of the British Journal of Cancer, four
independent studies provide new data that furthers our under-
standing of CRC genetics. Two of these studies focus on novel
gene discovery and the mechanistic understanding of highly
penetrant CRC forms, whereas the other two papers focus on
GWAS and post-GWAS approaches to study CRC aetiology and
survival.
NEW GENES AND NEW MECHANISMS
Evidence for a new risk variant on chromosome 1q32 was
provided by Schubert et al.,10 building on previous studies that
demonstrated the association of a nearby region (1q41) with the
risk of CRC and multiple adenomas.11,12 The authors used two
independent gene identification approaches (homozygosity map-
ping and linkage analysis) to identify a rare non-synonymous
single-nucleotide variant (nsSNP, p.Asp1432Glu) in the MIA3 gene
(also known as TANGO, a gene not previously known to be
associated with CRC). Co-segregation studies together with
tumour gene and protein expression analyses provided support-
ing data for a role of TANGO p.Asp1432Glu in CRC tumourigenesis.
Further independent studies are warranted to confirm the causal
role of this TANGO variant in CRC.
The second study focussed on understanding the mechanisms
by which epigenetic mutations lead to CRC in Lynch Syndrome
(LS), the most common CRC-predisposing syndrome.13 Estela
Dámaso and collaborators14 investigated the mechanism under-
lying constitutional primary MLH1 epimutations. Individuals with
these epimutations represent around 2% of all mutation-negative
cases suspected of LS and typically have severe CRC manifesta-
tions.15 In this condition, MLH1 epimutations typically arise de
novo and lead to the soma-wide inactivation of the MLH1 allele
by methylation, which in turns leads to CRC. MLH1, a DNA
mismatch repair gene, is also methylated in sporadic CRC where it
explains most CRCs with microsatellite instability. Yet the
manifestation is different between sporadic CRC and constitu-
tional primary MLH1 epimutation, with the sporadic manifestation
exhibiting a colorectal tissue-specific alteration, rather than soma-
wide. In their study, 12 constitutional primary MLH1 epimutation
carriers along with 61 LS patients and 41 controls were analysed
with genome-wide methylation arrays to identify differentially
methylated regions (DMRs) between epimutation and non-
epimutation carriers. This analysis found that the only DMR was
a CpG island encompassing the MLH1 and EPM2AIP1 genes,
suggesting that constitutional primary MLH1 epimutation-driven
CRCs are different from sporadic MLH1 methylated CRCs, where
they exhibit a focal, rather than genome-wide, methylation
pattern.
Analysing the heritability of MLH1 epimutations, the authors
revealed that the epimutations were neither inherited nor passed
to descendants, because they were not detected in affected
relatives despite harbouring the epimutation-bearing haplotype.
This latter result is important, because it shows that constitutional
primary MLH1 epimutations experience inter-generation erasure.
Such information is important for genetic counselling of MLH1
epimutation carriers and for our understanding of CRC tumour-
igenesis in patients with this condition.
GENETIC AETIOLOGY, FUNCTIONAL STUDIES AND STUDYING
THE GENETICS OF CRC SURVIVAL
Most GWAS-identified variants map to non-coding regions, and
they likely increase risk by regulating transcript levels of nearby
genes.8 Identifying genes whose transcripts are under genetic
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control (called eGenes) is thus useful to discover new CRC variants
and to understand the mechanisms by which GWAS alleles
increase CRC risk. In order to link genetic variation with gene
expression patterns, Moreno et al.16 discovered expression
quantitative trait loci (eQTLs) in colon tissue from paired colon
tumour/adjacent normal samples and from normal colonic
biopsies obtained from healthy donors. The study identified 363
colonic eGenes, many of which overlapped with those in GTEx (a
publicly available eQTL database) or with those identified in a
previous study.17 Interestingly, of the 37,099 eQTLs discovered in
this study, only 4,858 were identified both in normal and tumour
tissue, raising the possibility that some of these might be good
candidates for CRC tumourigenesis studies. These data are now
publicly available through a dedicated website and they represent
a great resource in post-GWAS studies of CRC. The final study was
aimed at identifying nsSNPs affecting CRC survival.18 Despite
having sufficient statistical power in this GWAS study to detect
nsSNPs with modest effects on survival, the study failed to find
genome-wide significant associations, suggesting that survival
may be influenced by rarer nsSNPs or by common non-coding
variants. Future studies, therefore, should not only increase
sample size to enable the detection of milder effects but should
also include additional types of genetic variation that may have
effects on prognosis.
The studies published in this issue help move the needle
towards an improved understanding of the role of genetic factors
in CRC aetiology and survival. They show that multiple approaches
are needed to identify and characterise CRC genes and suggest
that future studies, particularly those focussing on complex
phenotypes such as survival, will require collaborative efforts by
the international research community.
DISCLAIMER
The content is solely the responsibility of the author and does not
necessarily represent the official views of the National Institutes of
Health.
ACKNOWLEDGEMENTS
L.G.C.-C. receives funding from the University of California Davis School of Medicine
(Dean's Fellowship in Precision Medicine) and from the National Cancer Institute
(P30CA093373) and National Institute of Environmental health Sciences
(P30ES023513) of the National Institutes of Health.
ADDITIONAL INFORMATION
Competing interests: The author declares no competing interests.
Note: This work is published under the standard license to publish agreement. After
12 months the work will become freely available and the license terms will switch to
a Creative Commons Attribution 4.0 International (CC BY 4.0).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Luis G. Carvajal-Carmona 1,2,3
1Genome Center, University of California, Davis, CA, USA; 2UC Davis
Comprehensive Cancer Center, School of Medicine, University of
California, Davis, CA, USA and 3Department of Biochemistry and
Molecular Medicine, School of Medicine, University of California,
Davis, CA, USA
Correspondence: Luis G. Carvajal-Carmona (lgcarvajal@ucdavis.edu)
REFERENCES
1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and
major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–386 (2015).
2. Zauber, A. G. et al. Colonoscopic polypectomy and long-term prevention of
colorectal-cancer deaths. N. Engl. J. Med. 366, 687–696 (2012).
3. Logan, R. F. et al. Outcomes of the Bowel Cancer Screening Programme (BCSP) in
England after the first 1 million tests. Gut 61, 1439–1446 (2012).
4. Morris, E. J. et al. A retrospective observational study examining the character-
istics and outcomes of tumours diagnosed within and without of the English NHS
Bowel Cancer Screening Programme. Br. J. Cancer 107, 757–764 (2012).
5. Cole, S. R. et al. Shift to earlier stage at diagnosis as a consequence of
the National Bowel Cancer Screening Program. Med. J. Aust. 198, 327–330 (2013).
6. Lichtenstein, P. et al. Environmental and heritable factors in the causation of
cancer — analyses of cohorts of twins from Sweden, Denmark, and Finland. N.
Engl. J. Med. 343, 78–85 (2000).
7. Carvajal Carmona, L. G. & Tomlinson, I. The hunting of the snark: whither
genome-wide association studies for colorectal cancer? Gastroenterology 150,
1528–1530 (2016).
8. Sud, A., Kinnersley, B. & Houlston, R. S. Genome-wide association studies of
cancer: current insights and future perspectives. Nat. Rev. Cancer 17, 692–704
(2017).
9. Jiao, S. et al. Estimating the heritability of colorectal cancer. Hum. Mol. Genet. 23,
3898–3905 (2014).
10. Schubert, S. A. et al. Evidence for genetic association between chromosome 1q
loci and predisposition to colorectal neoplasia. Br. J. Cancer 117, 1215–1223 (2017).
11. Montazeri, Z. et al. Systematic meta-analyses and field synopsis of genetic
association studies in colorectal adenomas. Int. J. Epidemiol. 45, 186–205
(2016).
12. Spain, S. L. et al. Refinement of the associations between risk of colorectal cancer
and polymorphisms on chromosomes 1q41 and 12q13.13. Hum. Mol. Genet. 21,
934–946 (2012).
13. Lynch, H. T. et al. Review of the Lynch syndrome: history, molecular genetics,
screening, differential diagnosis, and medicolegal ramifications. Clin. Genet. 76,
1–18 (2009).
14. Dámaso, E. et al. Primary constitutional mlh1 epimutations: a focal epigenetic
event. Br. J. Cancer (2018).
15. Hitchins, M. P. Finding the needle in a haystack: identification of cases of Lynch
syndrome with MLH1 epimutation. Fam. Cancer 15, 413–422 (2016).
16. Moreno, V., et al. Colon-specific eQTL analysis to inform on functional SNPs. Br. J.
Cancer (2018).
17. Ongen, H. et al. Putative cis-regulatory drivers in colorectal cancer. Nature 512,
87–90 (2014).
18. Theodoratou, E., et al. Genome-wide scan of the effect of common nsSNPs on
colorectal cancer survival outcome. Br. J. Cancer (2018).
Editorial
914
1
2
3
4
5
6
7
8
9
0
()
;,:
